Towards efficient cancer immunotherapy: Advances in developing artificial antigen-presenting cells

Trends in Biotechnology

Volumn 32, Issue 9, 2014, Pages 456-465

  Eggermont, Loek J ^a   Paulis, Leonie E ^a   Tel, Jurjen ^a   Figdor, Carl G ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Artificial antigen presenting cell; Cancer; Immunotherapy; Synthetic dendritic cell

Indexed keywords

ANTIGENS; CELLS; CYTOLOGY;

ANTIGEN PRESENTING CELLS; CANCER; CANCER IMMUNOTHERAPY; CO-STIMULATORY SIGNAL; DENDRITIC CELLS; IMMUNO MODULATIONS; IMMUNOTHERAPY; T CELL ACTIVATION;

DISEASES;

CARBON NANOTUBE; LIPOSOME; POLYSTYRENE;

ANTIGEN PRESENTING CELL; CANCER IMMUNOTHERAPY; CELL SHAPE; CELL SIZE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; HUMAN; IMMUNOMODULATION; LIPID BILAYER; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; TREATMENT RESPONSE; ARTIFICIAL CELL; IMMUNOLOGY; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; MEDICAL RESEARCH; NEOPLASMS; PHYSIOLOGY; PROCEDURES; TRENDS;

ANTIGEN-PRESENTING CELLS; ARTIFICIAL CELLS; BIOMEDICAL RESEARCH; HUMANS; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84906316004     PISSN: 01677799     EISSN: 18793096     Source Type: Journal    
DOI: 10.1016/j.tibtech.2014.06.007     Document Type: Review

References (87)

1. Weiner L.M., et al. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat. Rev. Immunol. 2010, 10:317-327.
2. Nelson A.L., et al. Development trends for human monoclonal antibody therapeutics. Nat. Rev. Drug Discov. 2010, 9:767-774.
3. Rosenberg S.A., Dudley M.E. Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr. Opin. Immunol. 2009, 21:233-240.
4. Kalos M., June C.H. Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology. Immunity 2013, 39:49-60.
5. Vonderheide R.H., June C.H. Engineering T cells for cancer: our synthetic future. Immunol. Rev. 2014, 257:7-13.
6. Palucka K., Banchereau J. Cancer immunotherapy via dendritic cells. Nat. Rev. Cancer 2012, 12:265-277.
7. Cheever M.A., Higano C.S. Provenge (sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine. Clin. Cancer Res. 2011, 17:3520-3526.
8. + T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:16168-16173.
9. Steenblock E.R., et al. Antigen presentation on artificial acellular substrates: modular systems for flexible, adaptable immunotherapy. Expert Opin. Biol. Ther. 2009, 9:451-464.
10. Melief C.J.M. Cancer immunotherapy by dendritic cells. Immunity 2008, 29:372-383.
11. Steinman R.M., Banchereau J. Taking dendritic cells into medicine. Nature 2007, 449:419-426.
12. Palucka K., Banchereau J. Dendritic-cell-based therapeutic cancer vaccines. Immunity 2013, 39:38-48.
13. + lymphocytes for adoptive therapy generated using an artificial antigen-presenting cell. Clin. Cancer Res. 2007, 13:1857-1867.
14. Kim J.V., et al. The ABCs of artificial antigen presentation. Nat. Biotechnol. 2004, 22:403-410.
15. Sunshine J.C., Green J.J. Nanoengineering approaches to the design of artificial antigen-presenting cells. Nanomedicine 2013, 8:1173-1189.
16. Turtle C.J., Riddell S.R. Artificial antigen-presenting cells for use in adoptive immunotherapy. Cancer J. 2010, 16:374-381.
17. + T cells: implications for tumor immunotherapy. Immunity 1996, 4:555-564.
18. Papanicolaou G.A., et al. Rapid expansion of cytomegalovirus-specific cytotoxic T lymphocytes by artificial antigen-presenting cells expressing a single HLA allele. Blood 2003, 102:2498-2505.
19. Maus M.V., et al. Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB. Nat. Biotechnol. 2002, 20:143-148.
20. Butler M.O., Hirano N. Human cell-based artificial antigen-presenting cells for cancer immunotherapy. Immunol. Rev. 2014, 257:191-209.
21. Dupont J., et al. Artificial antigen-presenting cells transduced with telomerase efficiently expand epitope-specific, human leukocyte antigen-restricted cytotoxic T cells. Cancer Res. 2005, 65:5417-5427.
22. Mescher M.F. Surface contact requirements for activation of cytotoxic T lymphocytes. J. Immunol. 1992, 149:2402-2405.
23. + T cells. Eur. J. Immunol. 1997, 27:598-608.
24. Oelke M., et al. Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig-coated artificial antigen-presenting cells. Nat. Med. 2003, 9:619-624.
25. Lu X., et al. Adoptive transfer of pTRP2-specific CTLs expanding by bead-based artificial antigen-presenting cells mediates anti-melanoma response. Cancer Lett. 2008, 271:129-139.
26. Casey K.A., Mescher M.F. IL-21 promotes differentiation of naive CD8 T cells to a unique effector phenotype. J. Immunol. 2007, 178:7640-7648.
27. + T lymphocyte responses. Asian Pac. J. Trop. Med. 2013, 6:467-472.
28. Rudolf D., et al. Potent costimulation of human CD8 T cells by anti-4-1BB and anti-CD28 on synthetic artificial antigen presenting cells. Cancer Immunol. Immunother. 2008, 57:175-183.
29. + T cells are poorly costimulated by ICAM-1. Eur. J. Immunol. 1999, 29:45-53.
30. Corr M., et al. T cell receptor-MHC class I peptide interactions: affinity, kinetics, and specificity. Science 1994, 265:946-949.
31. + T cells. Clin. Immunol. 2003, 106:16-22.
32. Jiang X., et al. HLA tetramer based artificial antigen-presenting cells efficiently stimulate CTLs specific for malignant glioma. Clin. Cancer Res. 2007, 13:7329-7334.
33. Shen C., et al. Latex bead-based artificial antigen-presenting cells induce tumor-specific CTL responses in the native T-cell repertoires and inhibit tumor growth. Immunol. Lett. 2013, 150:1-11.
34. Oelke M., Schneck J.P. Overview of a HLA-Ig based 'Lego-like system' for T cell monitoring, modulation and expansion. Immunol. Res. 2010, 47:248-256.
35. Perica K., et al. Magnetic field-induced T cell receptor clustering by nanoparticles enhances T cell activation and stimulates antitumor activity. ACS Nano 2014, 8:2252-2260.
36. Perica K., et al. Nanoscale artificial antigen presenting cells for T cell immunotherapy. Nanomedicine 2014, 10:119-129.
37. + T cells in the absence of exogenous feeder cells. J. Immunol. 1997, 159:5921-5930.
38. Rapoport A.P., et al. Rapid immune recovery and graft-versus-host disease-like engraftment syndrome following adoptive transfer of costimulated autologous T cells. Clin. Cancer Res. 2009, 15:4499-4507.
39. Hardy N.M., et al. Phase I trial of adoptive cell transfer with mixed-profile type-I/type-II allogeneic T cells for metastatic breast cancer. Clin. Cancer Res. 2011, 17:6878-6887.
40. Porter D.L., et al. A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation. Blood 2006, 107:1325-1331.
41. Lum L.G., et al. Immune modulation in cancer patients after adoptive transfer of anti-CD3/anti-CD28-costimulated T cells - Phase I clinical trial. J. Immunother. 2001, 24:408-419.
42. Wuest S.C., et al. A role for interleukin-2 trans-presentation in dendritic cell-mediated T cell activation in humans, as revealed by daclizumab therapy. Nat. Med. 2011, 17:604-609.
43. Steenblock E.R., et al. An artificial antigen-presenting cell with paracrine delivery of IL-2 impacts the magnitude and direction of the T cell response. J. Biol. Chem. 2011, 286:34883-34892.
44. Fahmy T.M., et al. Surface modification of biodegradable polyesters with fatty acid conjugates for improved drug targeting. Biomaterials 2005, 26:5727-5736.
45. Steenblock E.R., Fahmy T.M. A comprehensive platform for ex vivo T-cell expansion based on biodegradable polymeric artificial antigen-presenting cells. Mol. Ther. 2008, 16:765-772.
46. Han H., et al. A novel system of artificial antigen-presenting cells efficiently stimulates Flu peptide-specific cytotoxic T cells in vitro. Biochem. Biophys. Res. Commun. 2011, 411:530-535.
47. Choudhuri K., et al. Polarized release of T-cell-receptor-enriched microvesicles at the immunological synapse. Nature 2014, 507:118-123.
48. Kaizuka Y., et al. Mechanisms for segregating T cell receptor and adhesion molecules during immunological synapse formation in Jurkat T cells. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:20296-20301.
49. Irvine D.J., Doh J. Synthetic surfaces as artificial antigen presenting cells in the study of T cell receptor triggering and immunological synapse formation. Semin. Immunol. 2007, 19:245-254.
50. Hsu C-J., et al. Ligand mobility modulates immunological synapse formation and T cell activation. PLoS ONE 2012, 7:e32398.
51. Doh J., Irvine D.J. Immunological synapse arrays: patterned protein surfaces that modulate immunological synapse structure formation in T cells. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:5700-5705.
52. + T cell function. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:7791-7796.
53. Shen K., et al. Nanoengineering of immune cell function. Mater. Res. Soc. Symp. Proc. 2009, 1209.
54. Dustin M.L., et al. Understanding the structure and function of the immunological synapse. Cold Spring Harb. Perspect. Biol. 2010, 2:a002311.
55. Prakken B., et al. Artificial antigen-presenting cells as a tool to exploit the immune 'synapse'. Nat. Med. 2000, 6:1406-1410.
56. + T cells using recombinant artificial APC: following the antiovalbumin immune response. J. Immunol. 2003, 170:123-131.
57. Anderson H.A., et al. Concentration of MHC class II molecules in lipid rafts facilitates antigen presentation. Nat. Immunol. 2000, 1:156-162.
58. + T cell activation and antigen-specific immune responses. Pharm. Res. 2013, 30:60-69.
59. Giannoni F., et al. Clustering of T cell ligands on artificial APC membranes influences T cell activation and protein kinase C θ translocation to the T cell plasma membrane. J. Immunol. 2005, 174:3204-3211.
60. Zappasodi R., et al. The effect of artificial antigen-presenting cells with preclustered anti-CD28/-CD3/-LFA-1 monoclonal antibodies on the induction of ex vivo expansion of functional human antitumor T cells. Haematologica 2008, 93:1523-1534.
61. Jin T., et al. Lipobeads: a hydrogel anchored lipid vesicle system. FEBS Lett. 1996, 397:70-74.
62. Hu C-M.J., et al. Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:10980-10985.
63. Ashley C.E., et al. The targeted delivery of multicomponent cargos to cancer cells by nanoporous particle-supported lipid bilayers. Nat. Mater. 2011, 10:389-397.
64. Goldstein S.A., Mescher M.F. Cell-sized, supported artificial membranes (pseudocytes): response of precursor cytotoxic T lymphocytes to class I MHC proteins. J. Immunol. 1986, 137:3383-3392.
65. Mescher M.F., Savelieva E. Stimulation of tumor-specific immunity using tumor cell plasma membrane antigen. Methods 1997, 12:155-164.
66. Yoo J.J-W., Mitragotri S. Polymer particles that switch shape in response to a stimulus. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:11205-11210.
67. + T cell activation by artificial antigen presenting cells. Biomaterials 2014, 35:269-277.
68. Fadel T.R., et al. Enhanced cellular activation with single walled carbon nanotube bundles presenting antibody stimuli. Nano Lett. 2008, 8:2070-2076.
69. Fadel T.R., et al. Clustering of stimuli on single-walled carbon nanotube bundles enhances cellular activation. Langmuir 2010, 26:5645-5654.
70. Fadel T.R., et al. Adsorption of multimeric T cell antigens on carbon nanotubes: effect on protein structure and antigen-specific T cell stimulation. Small 2013, 9:666-672.
71. Mandal S., et al. Therapeutic nanoworms: towards novel synthetic dendritic cells for immunotherapy. Chem. Sci. 2013, 4:4168.
72. Durai M., et al. In vivo functional efficacy of tumor-specific T cells expanded using HLA-Ig based artificial antigen presenting cells (aAPC). Cancer Immunol. Immunother. 2009, 58:209-220.
73. Mitchell M.S. Phase I trial of adoptive immunotherapy with cytolytic T lymphocytes immunized against a tyrosinase epitope. J. Clin. Oncol. 2002, 20:1075-1086.
74. Paulis L.E., et al. Dendritic cell-based nanovaccines for cancer immunotherapy. Curr. Opin. Immunol. 2013, 25:389-395.
75. Doshi N., et al. Red blood cell-mimicking synthetic biomaterial particles. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:21495-21499.
76. Merkel T.J., et al. Using mechanobiological mimicry of red blood cells to extend circulation times of hydrogel microparticles. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:586-591.
77. Champion J.A., et al. Particle shape: a new design parameter for micro- and nanoscale drug delivery carriers. J. Control. Release 2007, 121:3-9.
78. Han H., et al. Spatial charge configuration regulates nanoparticle transport and binding behavior in vivo. Angew. Chem. Int. Ed. Engl. 2013, 52:1414-1419.
79. Rogers J., Mescher M.F. Augmentation of in vivo cytotoxic T lymphocyte activity and reduction of tumor growth by large multivalent immunogen. J. Immunol. 1992, 149:269-276.
80. Mescher M.F., Rogers J.D. Immunotherapy of established murine tumors with large multivalent immunogen and cyclophosphamide. J. Immunother. Emphasis Tumor Immunol. 1996, 19:102-112.
81. Mitchell M.S. Phase I trial of large multivalent immunogen derived from melanoma lysates in patients with disseminated melanoma. Clin. Cancer Res. 2004, 10:76-83.
82. Dudek A.Z., et al. Autologous large multivalent immunogen vaccine in patients with metastatic melanoma and renal cell carcinoma. Am. J. Clin. Oncol. 2008, 31:173-181.
83. Shen C., et al. Induction of tumor antigen-specific cytotoxic T cell responses in naïve mice by latex microspheres-based artificial antigen-presenting cell constructs. Cell. Immunol. 2007, 247:28-35.
84. Ugel S., et al. In vivo administration of artificial antigen-presenting cells activates low-avidity T cells for treatment of cancer. Cancer Res. 2009, 69:9376-9384.
85. Park J., et al. Combination delivery of TGF-β inhibitor and IL-2 by nanoscale liposomal polymeric gels enhances tumour immunotherapy. Nat. Mater. 2012, 11:895-905.
86. Cai S., et al. Lymphatic drug delivery using engineered liposomes and solid lipid nanoparticles. Adv. Drug Deliv. Rev. 2011, 63:901-908.
87. + T cells. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:1969-1974.